Perindopril is an angiotensin converting enzyme inhibitor indicated for the treatment of patients with essential hypertension, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Perindopril for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction.
Source: US FDA prescribing information
Perindopril erbumine is a pro-drug for perindoprilat, which inhibits ACE in human subjects and animals. The mechanism through which perindoprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes conversion of the inactive decapeptide, angiotensin I, to the vasoconstrictor, angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor, which stimulates aldosterone secretion by the adrenal cortex, and provides negative feedback on renin secretion. Inhibition of ACE results in decreased plasma angiotensin II, leading to decreased vasoconstriction, increased plasma renin activity and decreased aldosterone secretion. The latter results in diuresis and natriuresis and may be associated with a small increase of serum potassium. ACE is identical to kininase II, an enzyme that degrades bradykinin.
Source: US FDA prescribing information
Hypertension The recommended initial dose is 4 mg once a day. The dosage may be titrated upward until blood pressure, when measured just before the next dose, is controlled or to a maximum of 16 mg per day. Stable Coronary Artery Disease Perindopril erbumine tablets should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased, as tolerated, to a maintenance dose of 8 mg once daily.
Source: US FDA prescribing information
Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. Perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes. Perindopril erbumine tablets are contraindicated in combination with neprilysin inhibitor (e.g., sacubitril). Do not administer perindopril erbumine tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor.
Source: US FDA prescribing information
Boxed warning (fetal toxicity): When pregnancy is detected, discontinue perindopril erbumine as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Watch for anaphylactoid reactions, including angioedema. Monitor renal function during therapy. Assess for hypotension and hyperkalemia.
Source: US FDA prescribing information
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypertension: Most common adverse events (incidence greater than or equal to 5%) are cough, dizziness and back pain. Stable Coronary Artery Disease: Most common adverse events leading to discontinuation were cough, drug intolerance, and hypotension.
Source: US FDA prescribing information
Diuretics: Excessive drop in blood pressure. Potassium-Sparing Diuretics/Potassium Supplements: Hyperkalemia. Lithium: Increase serum lithium levels, symptoms of lithium toxicity. Injectable Gold: Nitritoid reactions (facial flushing, nausea, vomiting, and hypotension). NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect. Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. Neprilysin Inhibitor: risk of angioedema.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). Protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Perindopril, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Perindopril 2 mg tabletOralGeneric name | — | US FDA | Available on request |
| Perindopril 4 mg tabletOralGeneric name | — | US FDA | Available on request |
| Perindopril 8 mg tabletOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 December 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Perindopril in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Perindopril and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Perindopril on 30 December 1993, according to Drugs@FDA.
No listed presentation of Perindopril is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Perindopril is classified under ATC code C09AA04 (Perindopril).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.